EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Dexmedetomidine Attenuated Neuron Death, Cognitive Decline, and Anxiety-Like Behavior by Inhibiting CXCL2 in CA1 Region of AD Mice

Kaige Ma, Chanyuan An, Mai Li, Yuming Zhang, Minghe Ren iD, Yuyang Wei, Wenting Xu, Ruoxi Wang, Yudan Bai, Hanyue Zhang, Xiyue Liu, Shengfeng Ji und 2 weitere

Drug Design, Development and Therapy · 2024

DOI: 10.2147/dddt.s489860 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2024. Verfasst von Kaige Ma und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department/Institute of Neurobiology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, 710061, People's Repu…. Hauptthemen laut MEDLINE: Dexmedetomidine, Alzheimer Disease, Cognitive Dysfunction, Anxiety. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose: β-amyloid overload-induced neuroinflammation and neuronal loss are key pathological changes that occur during the progression of Alzheimer's disease (AD). Dexmedetomidine (Dex) exhibits neuroprotective and anti-inflammatory effects on the nervous system. However, the effect of Dex in AD mice remains unclear, and its neuroprotective regulatory mechanism requires further investigation. This study aimed to reveal how Dex protects against Aβ induced neuropathological changes and behavior dysfunction in AD mice.

Methods

An AD mouse model was established by the injection of Aβ into the brains of mice, followed by intraperitoneal injection with Dex. CXCL2 overexpression and Yohimbine, a Dex inhibitor, were used to investigate the role of Dex and CXCL2 in the regulation of neuronal loss, cognitive decline, and anxiety-like behavior in AD mice. Behavioral tests were performed to evaluate the cognitive and anxiety status of the mice. Nissl staining and immunofluorescence experiments were conducted to evaluate the status of the hippocampal neurons and astrocytes. qRT-PCR was performed to detect the expression of CXCL2, IL-1β, INOS, SPHK1, Bcl2, IFN-γ, and Caspase 1. The malondialdehyde (MDA) level was detected using an ELISA kit. Terminal TUNEL and Fluoro-Jade C (FJC) staining were used to measure the cell apoptosis rate.

Results

In AD mice, cognitive decline and anxiety-like behaviors were significantly improved by the Dex treatment. The number of neurons was increased in mice in the Dex + AD group compared to those in the AD group, and the number of astrocytes was not significantly different between the two groups. CXCL2, IL-1β, iNOS, and SPHK1 levels were significantly lower in Dex-treated AD mice than those in AD mice. Overloading of CXCL2 or Yohimbine reversed the protective effect of Dex on neuron number and cognitive and anxiety symptoms in AD mice.

Conclusion

Our results suggest that Dex exerts neuroprotective effects by downregulating CXCL2. Dex shows potential as a therapeutic drug for AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DexmedetomidineAlzheimer DiseaseCognitive DysfunctionAnxietyChemokine CXCL2NeuronsDisease Models, AnimalAnimalsMiceMaleNeuroprotective AgentsCell DeathAmyloid beta-PeptidesMice, Inbred C57BL

Stichwörter der Autor:innen

Alzheimer’s diseaseanxietybehavioral Testschemokine CXCL2cognitive dysfunctiondexamethasone

Substanzen

DexmedetomidineChemokine CXCL2Cxcl2 protein, mouseNeuroprotective AgentsAmyloid beta-Peptides

Autor:innen und Institutionen

  • Department/Institute of Neurobiology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, 710061, People's Republic of China.
  • Department of Anesthesiology, Shaanxi Provincial People's Hospital, Xi'an, 710068, People's Republic of China.
  • School of Forensic Medicine, Southern Medical University, Guangdong, 510515, People's Republic of China.
  • Department of Optometry, Fenyang College Shanxi Medical University, Fenyang, 032200, People's Republic of China.
  • Department of Human Anatomy, Histology and Embryology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, 710061, People's Republic of China.
  • Department of Neurology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, People's Republic of China.

ORCID-Profile: Minghe Ren

Zitieren

APA

Ma, K., An, C., Li, M., Zhang, Y., Ren, M., Wei, Y., Xu, W., Wang, R., Bai, Y., Zhang, H., Liu, X., Ji, S., Chen, X., & Zhu, K. (2024). Dexmedetomidine Attenuated Neuron Death, Cognitive Decline, and Anxiety-Like Behavior by Inhibiting CXCL2 in CA1 Region of AD Mice. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s489860

Vancouver

Ma K, An C, Li M, Zhang Y, Ren M, Wei Y, et al. Dexmedetomidine Attenuated Neuron Death, Cognitive Decline, and Anxiety-Like Behavior by Inhibiting CXCL2 in CA1 Region of AD Mice. Drug Design, Development and Therapy. 2024. doi:10.2147/dddt.s489860

BibTeX
@article{Ma2024,
  author = {Ma, Kaige and An, Chanyuan and Li, Mai and Zhang, Yuming and Ren, Minghe and Wei, Yuyang and Xu, Wenting and Wang, Ruoxi and Bai, Yudan and Zhang, Hanyue and Liu, Xiyue and Ji, Shengfeng and Chen, Xinlin and Zhu, Kun},
  title = {Dexmedetomidine Attenuated Neuron Death, Cognitive Decline, and Anxiety-Like Behavior by Inhibiting CXCL2 in CA1 Region of AD Mice},
  journal = {Drug Design, Development and Therapy},
  year = {2024},
  doi = {10.2147/dddt.s489860}
}
Kostenlos starten →